NEW YORK and CAMBRIDGE, Mass. — November 4, 2025 — Leads & Copy — Royalty Pharma plc (Nasdaq: RPRX) has acquired a royalty interest in Alnylam’s AMVUTTRA from Blackstone Life Sciences for $310 million. The royalty interest stems from Blackstone’s 2020 financing collaboration with Alnylam, where Blackstone invested to support AMVUTTRA’s pivotal Phase 3 HELIOS-B trial.
AMVUTTRA, an FDA-approved RNAi therapeutic, treats ATTR amyloidosis, a progressive and fatal disease caused by misfolded proteins accumulating in nerves, heart, and the GI tract. Pablo Legorreta, founder and CEO of Royalty Pharma, expressed delight in acquiring the royalty interest, citing AMVUTTRA’s benefits and commercial trajectory.
AMVUTTRA received FDA approval for ATTR-CM in 2025 and hATTR-PN in 2022. In 2024, sales reached approximately $1 billion, representing 74% year-over-year growth, and are projected to exceed $6 billion by 2028 based on analyst consensus.
Royalty Pharma acquired Blackstone’s 1% royalty on worldwide net sales of AMVUTTRA for $310 million upfront. The royalty extends through March 2035 and excludes fixed payments paid to Blackstone.
Gibson Dunn, Dechert and Maiwald acted as legal advisors to Royalty Pharma. Ropes & Gray and TD Securities acted as advisors to Blackstone.
Royalty Pharma Investor Relations and Communications:
+1 (212) 883-6637
ir@royaltypharma.com
Blackstone Communications:
David Vitek
(212) 583-5291
David.Vitek@blackstone.com
Source: Royalty Pharma
